Scarica l'app Stockscreener
128.68
4.03%
5.0661
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$123.61
Aprire:
$124.33
Volume 24 ore:
4.44M
Relative Volume:
0.44
Capitalizzazione di mercato:
$317.82B
Reddito:
$65.51B
Utile/perdita netta:
$8.93B
Rapporto P/E:
36.21
EPS:
3.5532
Flusso di cassa netto:
$14.12B
1 W Prestazione:
+2.81%
1M Prestazione:
+11.65%
6M Prestazione:
+18.16%
1 anno Prestazione:
+56.00%
Intervallo 1D:
$124.00
$128.73
Intervallo di 1 settimana:
$120.16
$128.57
Portata 52W:
$76.66
$130.29
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
128.68 | 305.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,175.40 | 1.03T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
250.24 | 594.63B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
252.39 | 431.29B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
152.97 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-02-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-13 | Ripresa | Citigroup | Neutral |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement - TradingKey
Merck's cholesterol pill gets US FDA approval - Reuters
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled - TradingKey
Earnings preview: What to expect from Merck & Co.'s report - MSN
Earnings Preview: What To Expect From Merck & Co.'s Report - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating - marketscreener.com
Why Merck Stock Is in the Spotlight Today - Benzinga
Merck stock holds steady after a research update - ad-hoc-news.de
Merck stock holds steady as analysts assess its pipeline - ad-hoc-news.de
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500 - ad-hoc-news.de
Merck & Co. stock holds steady as oncology and vaccines underpin long-term growth - AD HOC NEWS
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co. Inc. updates its oncology pipeline as a major S&P 500 healthcare player - AD HOC NEWS
Merck & Co. focuses on oncology and vaccines as a major global pharma player - Ad-hoc-news.de
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds - IPO Edge
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term gro - Ad-hoc-news.de
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Merck & Co. focuses on oncology pipeline as investors watch long-term growth - Ad-hoc-news.de
Merck & Co. Inc. balances pharmaceuticals growth and pipeline investment - Ad-hoc-news.de
Merck & Co (MRK) BofA Securities 2025 Healthcare Conference Summary - Quartr
Merck & Co. highlights its pharmaceutical portfolio as investors track long-term growth prospects - AD HOC NEWS
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Merck & Co. highlights its pharmaceuticals strength as investors track long term growth - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as a major global healthcare player - AD HOC NEWS
Merck & Co. looks to long-term growth as a global pharmaceutical leader - AD HOC NEWS
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co. focuses on oncology and vaccines as investors watch long-term growth - AD HOC NEWS
HSBC Adjusts Price Target on Merck & Co to $150 From $135 - Moomoo
Rothschild & Co Redburn Adjusts Price Target on Merck to $145 From $140 - Moomoo
Merck & Company, Inc. (MRK): Investor Outlook with a 2.62% Dividend Yield and Robust Buy Ratings - DirectorsTalk Interviews
Enterprise value to revenue forward of Merck & Co., Inc. – BX:6MK - TradingView
Redwood Grove Capital, LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
ETFs Investing in Merck & Co., Inc. Stocks - TradingView
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Te - GuruFocus
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send? - TradingKey
Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up (NYSE:MRK) - Seeking Alpha
MRKMerck & Co Inc Volatility & Greeks - Finviz
Merck & Co. focuses on long-term growth as a global healthcare leader - AD HOC NEWS
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - BioSpace
Merck & Co | 4: Statement of changes in beneficial ownership of securities-Director Seidman Christine E - Moomoo
Merck (NYSE: MRK) director granted phantom stock in deferred pay plan - Stock Titan
Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says - Moomoo
Merck & Co earnings guidance frames 2026 outlook. Technicals show MRK trading in a tight range - AD HOC NEWS
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):